Skip to content
2000
Volume 25, Issue 16
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Cancer, with a high incidence and mortality rate, has emerged as a major public health problem worldwide. Currently, new approaches, such as targeted therapy and immunotherapy, are giving hope to patients. However, drug resistance and adverse side effects are major barriers to cancer treatment. As a result, there is a greater focus on the development of cancer therapy strategies and medications with low toxicity and high efficacy. Cryptotanshinone (CTS), a diterpenoid quinone extracted from , exhibits a wide range of biological activities, including immunomodulatory, anti-inflammatory, and antitumor effects. In recent years, numerous studies have highlighted its significant antitumor properties, indicating potential clinical applications and development value. However, the clinical use of cryptotanshinone has been limited due to its poor water solubility and low bioavailability. To overcome these limitations, researchers are exploring new drug delivery systems, and novel formulation systems based on nanotechnology are being developed to improve the delivery and effectiveness of cryptotanshinone. In this review, we aim to consolidate the existing knowledge regarding the antitumor effects of cryptotanshinone and emphasize the latest advancements in its nanoformulation development. We hope to provide insights that will further improve the antitumor efficacy and clinical applicability of cryptotanshinone.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206372305250319064431
2025-10-01
2026-03-06

  • From This Site

    /content/journals/acamc/10.2174/0118715206372305250319064431
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SiegelR.L. GiaquintoA.N. JemalA. Cancer statistics, 2024.CA Cancer J. Clin.2024741124910.3322/caac.2182038230766
     [Google Scholar]
  2. DumbravaE.I. Meric-BernstamF. Personalized cancer therapy—leveraging a knowledge base for clinical decision-making.Mol. Case Stud.201842a00157810.1101/mcs.a00157829212833
     [Google Scholar]
  3. KhanS.U. FatimaK. AishaS. MalikF. Unveiling the mechanisms and challenges of cancer drug resistance.Cell Commun. Signal.202422110910.1186/s12964‑023‑01302‑138347575
     [Google Scholar]
  4. WangW. WangX. ZhangX. LiangC. Cryptotanshinone attenuates oxidative stress and inflammation through the regulation of Nrf‐2 and NF ‐κB in mice with unilateral ureteral obstruction.Basic Clin. Pharmacol. Toxicol.2018123671472010.1111/bcpt.1309129972887
     [Google Scholar]
  5. ChenW. LuY. ChenG. HuangS. Molecular evidence of cryptotanshinone for treatment and prevention of human cancer.Anticancer. Agents Med. Chem.201313797998710.2174/1871520611313999011523272908
     [Google Scholar]
  6. VundavilliH. DattaA. SimaC. HuaJ. LopesR. BittnerM. Targeting oncogenic mutations in colorectal cancer using cryptotanshinone.PLoS One2021162e024719010.1371/journal.pone.024719033596259
     [Google Scholar]
  7. QiP. LiY. LiuX. JafariF.A. ZhangX. SunQ. MaZ. Cryptotanshinone Suppresses Non-Small Cell Lung Cancer via microRNA-146a-5p/EGFR Axis.Int. J. Biol. Sci.20191551072107910.7150/ijbs.3127731182926
     [Google Scholar]
  8. DalilD. IranzadehS. KohansalS. Anticancer potential of cryptotanshinone on breast cancer treatment; A narrative review.Front. Pharmacol.20221397963410.3389/fphar.2022.97963436188552
     [Google Scholar]
  9. Estolano-CobiánA. AlonsoM.M. Díaz-RubioL. PonceC.N. Córdova-GuerreroI. MarreroJ.G. Tanshinones and their derivatives: Heterocyclic ring-fused diterpenes of biological interest.Mini Rev. Med. Chem.202121217118510.2174/138955752066620042910322532348220
     [Google Scholar]
  10. ZhouM. YiY. LiuL. LinY. LiJ. RuanJ. ZhongZ. Polymeric micelles loading with ursolic acid enhancing anti-tumor effect on hepatocellular carcinoma.J. Cancer201910235820583110.7150/jca.3086531737119
     [Google Scholar]
  11. WuY.H. WuY.R. LiB. YanZ.Y. Cryptotanshinone: A review of its pharmacology activities and molecular mechanisms.Fitoterapia202014510463310.1016/j.fitote.2020.10463332445662
     [Google Scholar]
  12. ChenY. LiuJ. ZhangJ. YangL. JinL. Research progress in the quality evaluation of Salvia miltiorrhiza based on the association of ‘morphological features — functional substances — pharmacological action — clinical efficacy’.Heliyon2023910e2032510.1016/j.heliyon.2023.e2032537780757
     [Google Scholar]
  13. JiangZ. GaoW. HuangL. Tanshinones, critical pharmacological components in Salvia miltiorrhiza. Front. Pharmacol.20191020210.3389/fphar.2019.0020230923500
     [Google Scholar]
  14. AngK.P. TanH.K. SelvarajaM. KadirA. SomchitM. AkimA. ZakariaZ. AhmadZ. Cryptotanshinone attenuates in vitro oxLDL-induced pre-lesional atherosclerotic events.Planta Med.201177161782178710.1055/s‑0030‑127111921614753
     [Google Scholar]
  15. MaheshR. JungH.W. KimG.W. KimY.S. ParkY.K. Cryptotanshinone from Salviae miltiorrhizae radix inhibits sodium-nitroprusside-induced apoptosis in neuro-2a cells.Phytother. Res.20122681211121910.1002/ptr.370522228596
     [Google Scholar]
  16. PengB. ZhangS.Y. ChanK.I. ZhongZ.F. WangY.T. Novel anti-cancer products targeting AMPK: Natural herbal medicine against breast cancer.Molecules202328274010.3390/molecules2802074036677797
     [Google Scholar]
  17. MaY. ShengJ. YanF. WeiW. LiL. LiuL. SunJ. Potential binding of cryptotanshinone with hemoglobin and antimetastatic effects against breast cancer cells through alleviating the expression of MMP-2/-9.Arab. J. Chem.2023161010507110.1016/j.arabjc.2023.105071
     [Google Scholar]
  18. zhangX. LiuM. YangF. MaL. Antiproliferative effect of cryptotanshinone against human non-small cell lung cancer cells through inactivation of lncRNA HOTAIR /p-Akt signaling pathway.Arab. J. Chem.202114610315010.1016/j.arabjc.2021.103150
     [Google Scholar]
  19. ShinD.S. KimH.N. ShinK.D. YoonY.J. KimS.J. HanD.C. KwonB.M. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells.Cancer Res.200969119320210.1158/0008‑5472.CAN‑08‑257519118003
     [Google Scholar]
  20. YaoY. LiH.Z. QianB.J. LiuC.M. ZhangJ.B. LinM.C. [Crypotanshione reduces the expression of metadherin in DU145 prostate cancer cells].Zhonghua Nan Ke Xue201521978278726552209
     [Google Scholar]
  21. LiH. GaoC. LiangQ. LiuC. LiuL. ZhuangJ. YangJ. ZhouC. FengF. SunC. Cryptotanshinone is a intervention for er-positive breast cancer: An integrated approach to the study of natural product intervention mechanisms.Front. Pharmacol.20211159210910.3389/fphar.2020.59210933505309
     [Google Scholar]
  22. ZhouJ. SuC.M. ChenH.A. DuS. LiC.W. WuH. TsaiS.H. YehY.T. Cryptanshinone inhibits the glycolysis and inhibits cell migration through PKM2/β-catenin axis in breast cancer.OncoTargets Ther.2020138629863910.2147/OTT.S23913432922039
     [Google Scholar]
  23. WangY. LuH. LiuY. YangL. JiangQ. ZhuX. FanH. QianY. Cryptotanshinone sensitizes antitumor effect of paclitaxel on tongue squamous cell carcinoma growth by inhibiting the JAK/STAT3 signaling pathway.Biomed. Pharmacother.2017951388139610.1016/j.biopha.2017.09.06228946186
     [Google Scholar]
  24. JiangG. LiuJ. RenB. ZhangL. OwusuL. LiuL. ZhangJ. TangY. LiW. Anti-tumor and chemosensitization effects of Cryptotanshinone extracted from Salvia miltiorrhiza Bge. on ovarian cancer cells in vitro.J. Ethnopharmacol.2017205334010.1016/j.jep.2017.04.02628456578
     [Google Scholar]
  25. XuZ. JiangH. ZhuY. WangH. JiangJ. ChenL. XuW. HuT. ChoC.H. Cryptotanshinone induces ROS-dependent autophagy in multidrug-resistant colon cancer cells.Chem. Biol. Interact.2017273485510.1016/j.cbi.2017.06.00328600121
     [Google Scholar]
  26. XiaC. BaiX. HouX. GouX. WangY. ZengH. HuangM. JinJ. Cryptotanshinone reverses cisplatin resistance of human lung carcinoma a549 cells through down-regulating NrF2 pathway.Cell. Physiol. Biochem.201537281682410.1159/00043039826356271
     [Google Scholar]
  27. ZhuG. LiD. WangX. GuoQ. ZhaoY. HouW. LiJ. ZhengQ. Drug monomers from Salvia miltiorrhiza Bge. promoting tight junction protein expression for therapeutic effects on lung cancer.Sci. Rep.20231312292810.1038/s41598‑023‑50163‑838129556
     [Google Scholar]
  28. BlasiusR. ReuterS. HenryE. DicatoM. DiederichM. Curcumin regulates signal transducer and activator of transcription (STAT) expression in K562 cells.Biochem. Pharmacol.200672111547155410.1016/j.bcp.2006.07.02916959222
     [Google Scholar]
  29. LiuW. YuB. XuG. XuW.R. LohM.L. TangL.D. QuC.K. Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).J. Med. Chem.201356187212722110.1021/jm400474r23957426
     [Google Scholar]
  30. KimE.J. KimS.Y. KimS.M. LeeM. A novel topoisomerase 2a inhibitor, cryptotanshinone, suppresses the growth of PC3 cells without apparent cytotoxicity.Toxicol. Appl. Pharmacol.2017330849210.1016/j.taap.2017.07.00728716507
     [Google Scholar]
  31. MaoD. WangH. GuoH. CheX. ChenM. LiX. LiuY. HuoJ. ChenY. Tanshinone IIA normalized hepatocellular carcinoma vessels and enhanced PD-1 inhibitor efficacy by inhibiting ELTD1.Phytomedicine202412315519110.1016/j.phymed.2023.15519138000104
     [Google Scholar]
  32. ZhangJ. HuangM. GuanS. BiH.C. PanY. DuanW. ChanS.Y. ChenX. HongY.H. BianJ.S. YangH.Y. ZhouS. A mechanistic study of the intestinal absorption of cryptotanshinone, the major active constituent of Salvia miltiorrhiza.J. Pharmacol. Exp. Ther.200631731285129410.1124/jpet.105.10070116497784
     [Google Scholar]
  33. BiH.C. GuanS. ChenX. QiH.M. SuQ.B. HuangM. Implicit tanshinone in the small intestine absorption mechanism of experimental study.Chin. J. Clin. Pharmacol.200521107110
     [Google Scholar]
  34. XieM.Z. ShenZ.F. [Absorption, distribution, excretion and metabolism of cryptotanshinone].Yao. Xue. Xue. Bao.198318290966613598
     [Google Scholar]
  35. XueM. CuiY. WangH. LuoY. ZhangB. ZhouZ.T. Pharmacokinetics of CTS and its metabolite in pigs.Yao. Xue. Xue. Bao.1999348184
     [Google Scholar]
  36. XueM. CuiY. WangH.Q. HuZ. ZhangB. Reversed-phase liquid chromatographic determination of cryptotanshinone and its active metabolite in pig plasma and urine.J. Pharm. Biomed. Anal.199921120721310.1016/S0731‑7085(99)00098‑910701929
     [Google Scholar]
  37. QiuF. JiangJ. MaY. WangG. GaoC. ZhangX. ZhangL. LiuS. HeM. ZhuL. YeY. LiQ. MiaoP. Opposite effects of single-dose and multidose administration of the ethanol extract of Danshen on CYP3A in healthy volunteers.Evid. Based Complement. Alternat. Med.201320131810.1155/2013/73073424223062
     [Google Scholar]
  38. SankhwarM. SankhwarS.N. Variations in CYP isoforms and bladder cancer: A superfamily paradigm.Urol. Oncol.201432128.e3328.e4010.1016/j.urolonc.2012.10.00523428537
     [Google Scholar]
  39. ZengJ. FanY. TanB. SuH. LiY. ZhangL. JiangJ. QiuF. Charactering the metabolism of cryptotanshinone by human P450 enzymes and uridine diphosphate glucuronosyltransferases in vitro.Acta Pharmacol. Sin.20183981393140410.1038/aps.2017.14429417949
     [Google Scholar]
  40. MengZ. MengL. WangK. LiJ. CaoX. WuJ. HuY. Enhanced hepatic targeting, biodistribution and antifibrotic efficacy of tanshinone IIA loaded globin nanoparticles.Eur. J. Pharm. Sci.201573354310.1016/j.ejps.2015.03.00225769523
     [Google Scholar]
  41. LimcharoenB. ToprangkobsinP. BanlunaraW. WanichwecharungruangS. RichterH. LademannJ. PatzeltA. Increasing the percutaneous absorption and follicular penetration of retinal by topical application of proretinal nanoparticles.Eur. J. Pharm. Biopharm.20191399310010.1016/j.ejpb.2019.03.01430878519
     [Google Scholar]
  42. SalvioniL. MorelliL. OchoaE. LabraM. FiandraL. PaluganL. ProsperiD. ColomboM. The emerging role of nanotechnology in skincare.Adv. Coll. Interf. Sci.202129310243710.1016/j.cis.2021.10243734023566
     [Google Scholar]
  43. CabralH. MiyataK. OsadaK. KataokaK. Block copolymer micelles in nanomedicine applications.Chem. Rev.2018118146844689210.1021/acs.chemrev.8b0019929957926
     [Google Scholar]
  44. HwangD. RamseyJ.D. KabanovA.V. Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval.Adv. Drug Deliv. Rev.20201568011810.1016/j.addr.2020.09.00932980449
     [Google Scholar]
  45. WenY. JiaH. MoZ. ZhengK. ChenS. DingY. ZhangY. WenY. XieQ. QiuJ. WuH. NiQ. BanJ. LuZ. ChenY. Cross-linked thermosensitive nanohydrogels for ocular drug delivery with a prolonged residence time and enhanced bioavailability.Mater. Sci. Eng. C202111911144510.1016/j.msec.2020.11144533321585
     [Google Scholar]
  46. LiuY. XieX. HouX. ShenJ. ShiJ. ChenH. HeY. WangZ. FengN. Functional oral nanoparticles for delivering silibinin and cryptotanshinone against breast cancer lung metastasis.J. Nanobiotech.20201818310.1186/s12951‑020‑00638‑x32473632
     [Google Scholar]
  47. WuD. ChenM. ZhengN. LuY. WangX. JiangC. XuH. The efficacy and safety of pH‐responsive and photothermal‐sensitive multifunctional nanoparticles loaded with cryptotanshinone for the treatment of gastric cancer.Mol. Carcinog.202463122346236210.1002/mc.2381439185663
     [Google Scholar]
  48. LiZ. WeiW. ZhangM. GuoX. ZhangB. WangD. JiangX. LiuF. TangJ. Cryptotanshinone‐doped photothermal synergistic mxene@pda nanosheets with antibacterial and anti‐inflammatory properties for wound healing.Adv. Healthc. Mater.20231228230106010.1002/adhm.20230106037387333
     [Google Scholar]
  49. CaiY. ZhangW. ChenZ. ShiZ. HeC. ChenM. Recent insights into the biological activities and drug delivery systems of tanshinones.Int. J. Nanomedicine20161112113026792989
     [Google Scholar]
  50. MalamY. LoizidouM. SeifalianA.M. Liposomes and nanoparticles: Nanosized vehicles for drug delivery in cancer.Trends Pharmacol. Sci.2009301159259910.1016/j.tips.2009.08.00419837467
     [Google Scholar]
  51. LiuK. ZhaoB.L. SunZ.H. LuoN.N. LiX.F. Cryptotanshinone-loaded biomimetic pH-sensitive liposomes for the treatment of liver fibrosis.J. Drug Deli. Sci. Tech.202510410649610.1016/j.jddst.2024.106496
     [Google Scholar]
  52. ElBayoumiT.A. TorchilinV.P. Current trends in liposome research.Methods Mol. Biol.201060512710.1007/978‑1‑60327‑360‑2_120072870
     [Google Scholar]
  53. ZhaoH.C. WangY.M. CuiJ.W. FengK.H. WangR.N. DiL.Q. Construction of targeted cryptotanshinone liposomes and research on its in vitro anti-glioma effect.Yao Xue Xue Bao20215632683276
     [Google Scholar]
  54. WangX. WanW. ZhangJ. LuJ. LiuP. Efficient pulmonary fibrosis therapy via regulating macrophage polarization using respirable cryptotanshinone-loaded liposomal microparticles.J. Control. Release202436611710.1016/j.jconrel.2023.12.04238154539
     [Google Scholar]
  55. PaliwalR. PaliwalS.R. KenwatR. KurmiB.D. SahuM.K. Solid lipid nanoparticles: A review on recent perspectives and patents.Expert Opin. Ther. Pat.202030317919410.1080/13543776.2020.172064932003260
     [Google Scholar]
  56. WeyhersH. EhlersS. HahnH. SoutoE.B. MüllerR.H. Solid lipid nanoparticles (SLN)--effects of lipid composition on in vitro degradation and in vivo toxicity.Pharmazie200661653954416826974
     [Google Scholar]
  57. HuL. XingQ. MengJ. ShangC. Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles.AAPS Pharm. Sci. Tech.201011258258710.1208/s12249‑010‑9410‑320352534
     [Google Scholar]
  58. SzenteL. SzejtliJ. KisG.L. Spontaneous opalescence of aqueous gamma-cyclodextrin solutions: Complex formation or self-aggregation?J. Pharm. Sci.199887677878110.1021/js97043419607959
     [Google Scholar]
  59. LoftssonT. BrewsterM.E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization.J. Pharm. Sci.199685101017102510.1021/js950534b8897265
     [Google Scholar]
  60. ChallaR. AhujaA. AliJ. KharR.K. Cyclodextrins in drug delivery: An updated review.AAPS PharmSciTech200562E329E35710.1208/pt06024316353992
     [Google Scholar]
  61. PanY. BiH.C. ZhongG.P. ChenX. ZuoZ. ZhaoL.Z. GuL.Q. LiuP.Q. HuangZ.Y. ZhouS.F. HuangM. Pharmacokinetic characterization of hydroxylpropyl- β -cyclodextrin-included complex of cryptotanshinone, an investigational cardiovascular drug purified from Danshen ( Salvia miltiorrhiza ).Xenobiotica200838438239810.1080/0049825070182768518340563
     [Google Scholar]
  62. JørgensenS.S.D. SawafA.M. GraeserK. MuH. MüllertzA. RadesT. The ability of two in vitro lipolysis models reflecting the human and rat gastro-intestinal conditions to predict the in vivo performance of SNEDDS dosing regimens.Eur. J. Pharm. Biopharm.201812411612410.1016/j.ejpb.2017.12.01429288805
     [Google Scholar]
  63. PoutonC.W. Lipid formulations for oral administration of drugs: Non-emulsifying, self-emulsifying and ‘self-microemulsifying’ drug delivery systems.Eur. J. Pharm. Sci.200011Suppl. 2S93S9810.1016/S0928‑0987(00)00167‑611033431
     [Google Scholar]
  64. V Ramana RaoS. ShaoJ. Self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of protein drugs.Int. J. Pharm.20083621-22910.1016/j.ijpharm.2008.05.01818650038
     [Google Scholar]
  65. BiX. LiuX. DiL. ZuQ. Improved oral bioavailability using a solid self-microemulsifying drug delivery system containing a multicomponent mixture extracted from salvia miltiorrhiza.Molecules201621445610.3390/molecules2104045627070565
     [Google Scholar]
  66. JunghannsJ.U. MüllerR.H. Nanocrystal technology, drug delivery and clinical applications.Int. J. Nanomed.20083329530918990939
     [Google Scholar]
  67. LiJ. WangZ. ZhangH. GaoJ. ZhengA. Progress in the development of stabilization strategies for nanocrystal preparations.Drug Deliv.2021281193610.1080/10717544.2020.185622433336609
     [Google Scholar]
  68. GigliobiancoM.R. CasadidioC. CensiR. MartinoD.P. Nanocrystals of poorly soluble drugs: Drug bioavailability and physicochemical stability.Pharmaceutics201810313410.3390/pharmaceutics1003013430134537
     [Google Scholar]
  69. ZhangJ. XuW. MengF. YiT. A spray-dried self-stabilizing nanocrystal emulsion of traditional chinese medicine: Preparation, characterization and ex vivo intestinal absorption.Pharmaceutical Fronts202464e449e45810.1055/s‑0044‑1791831
     [Google Scholar]
  70. McKeeJ. RabinowB. CookC. GassJ. Nanosuspension formulation of itraconazole eliminates the negative inotropic effect of SPORANOX in dogs.J. Med. Toxicol.20106333133610.1007/s13181‑010‑0025‑620238196
     [Google Scholar]
  71. BarleE.L. ČerneM. PeternelL. HomarM. Reduced intravenous toxicity of amiodarone nanosuspension in mice and rats.Drug Chem. Toxicol.201336326326910.3109/01480545.2012.71062822950665
     [Google Scholar]
  72. ZhaoW. RuanB. SunX. YuZ. Preparation and optimization of surface stabilized cryptotanshinone nanocrystals with enhanced bioavailability.Front. Pharmacol.202314112207110.3389/fphar.2023.112207136817118
     [Google Scholar]
  73. BozzutoG. MolinariA. Liposomes as nanomedical devices.Int. J. Nanomed.20151097599910.2147/IJN.S6886125678787
     [Google Scholar]
  74. Sánchez-LópezE. GuerraM. Dias-FerreiraJ. Lopez-MachadoA. EttchetoM. CanoA. EspinaM. CaminsA. GarciaM.L. SoutoE.B. Current Applications of Nanoemulsions in Cancer Therapeutics.Nanomaterials20199682110.3390/nano906082131159219
     [Google Scholar]
  75. PanY. ShiJ. NiW. LiuY. WangS. WangX. WeiZ. WangA. ChenW. LuY. Cryptotanshinone inhibition of mammalian target of rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer.J. Cell. Mol. Med.20172192129213910.1111/jcmm.1313528272775
     [Google Scholar]
  76. ShiD. LiH. ZhangZ. HeY. ChenM. SunL. ZhaoP. Cryptotanshinone inhibits proliferation and induces apoptosis of breast cancer MCF-7 cells via GPER mediated PI3K/AKT signaling pathway.PLoS One2022171e026238910.1371/journal.pone.026238935061800
     [Google Scholar]
  77. ZhangW. YuW. CaiG. ZhuJ. ZhangC. LiS. GuoJ. YinG. ChenC. KongL. RETRACTED ARTICLE: A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy.Cell Death Dis.2018911109810.1038/s41419‑018‑1139‑z30368518
     [Google Scholar]
  78. ShiD. ZhaoP. CuiL. LiH. SunL. NiuJ. ChenM. Inhibition of PI3K/AKT molecular pathway mediated by membrane estrogen receptor GPER accounts for cryptotanshinone induced antiproliferative effect on breast cancer SKBR-3 cells.BMC Pharmacol. Toxicol.20202113210.1186/s40360‑020‑00410‑932357920
     [Google Scholar]
  79. NooriS. NourbakhshM. ImaniH. DeraviN. SalehiN. AbdolvahabiZ. Naringenin and cryptotanshinone shift the immune response towards Th1 and modulate T regulatory cells via JAK2/STAT3 pathway in breast cancer.BMC Complement. Med. Ther.202222114510.1186/s12906‑022‑03625‑x35606804
     [Google Scholar]
  80. YangY. CaoY. ChenL. LiuF. QiZ. ChengX. WangZ. Cryptotanshinone suppresses cell proliferation and glucose metabolism via STAT3/SIRT3 signaling pathway in ovarian cancer cells.Cancer Med.2018794610461810.1002/cam4.169130094960
     [Google Scholar]
  81. WangJ. ZhangG. DaiC. GaoX. WuJ. ShenL. ChenZ. LiuP. Cryptotanshinone potentiates the antitumor effects of doxorubicin on gastric cancer cells via inhibition of STAT3 activity.J. Int. Med. Res.201745122023010.1177/030006051668551328222632
     [Google Scholar]
  82. ZanrèV. CampagnariR. CerulliA. MasulloM. CardileA. PiacenteS. MenegazziM. Salviolone from Salvia miltiorrhiza roots impairs cell cycle progression, colony formation, and metalloproteinase-2 activity in a375 melanoma cells: Involvement of P21(Cip1/Waf1) expression and stat3 phosphorylation.Int. J. Mol. Sci.2022233112110.3390/ijms2303112135163058
     [Google Scholar]
  83. ChenL. ZhengS. SunZ. WangA. HuangC. PunchardN.A. HuangS. GaoX. LuY. Cryptotanshinone has diverse effects on cell cycle events in melanoma cell lines with different metastatic capacity.Cancer Chemother. Pharmacol.2011681172710.1007/s00280‑010‑1440‑820820782
     [Google Scholar]
  84. YenJ.H. HuangH.S. ChuangC.J. HuangS.T. Activation of dynamin-related protein 1 - dependent mitochondria fragmentation and suppression of osteosarcoma by cryptotanshinone.J. Exp. Clin. Cancer Res.20193814210.1186/s13046‑018‑1008‑830691497
     [Google Scholar]
  85. KeF. WangZ. SongX. MaQ. HuY. JiangL. ZhangY. LiuY. ZhangY. GongW. Cryptotanshinone induces cell cycle arrest and apoptosis through the JAK2/STAT3 and PI3K/Akt/NFkB pathways in cholangiocarcinoma cells.Drug Des. Devel. Ther.2017111753176610.2147/DDDT.S13248828670110
     [Google Scholar]
  86. ZhangL. YuL. WeiY. Oral administration of cryptotanshinone-encapsulated nanoparticles for the amelioration of ulcerative colitis.Cell. Mol. Bioeng.202215112913610.1007/s12195‑021‑00711‑x35096188
     [Google Scholar]
/content/journals/acamc/10.2174/0118715206372305250319064431
Loading
A Review of Cryptotanshinone and its Nanoformulation in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry 25, 1188 (2025); https://doi.org/10.2174/0118715206372305250319064431
/content/journals/acamc/10.2174/0118715206372305250319064431
/content/journals/acamc/10.2174/0118715206372305250319064431
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): antitumor effects; bioavailability; clinical applicability; Cryptotanshinone; drug formulation; nanotechnology

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test